Altimmune announces oral presentation of pemvidutide clinical data at 59th annual meeting of the european association for the study of diabetes

Gaithersburg, md., sept. 26, 2023 (globe newswire) -- altimmune, inc. (nasdaq: alt), a clinical-stage biopharmaceutical company, today announced that dr. louis j. aronne, founder and director of the center for weight management at weill-cornell medical center, and a leading authority in obesity, will present the results of its 24-week clinical trial of pemvidutide in the treatment of subjects with overweight or obesity in an oral presentation at the 59th annual meeting of the european association for the study of diabetes in hamburg, germany. pemvidutide is a novel, investigational, peptide-based glp-1/glucagon dual receptor agonist in development for the treatment of obesity and non-alcoholic steatohepatitis (nash).
ALT Ratings Summary
ALT Quant Ranking